BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19538112)

  • 1. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.
    Trotter CL; Maiden MC
    Expert Rev Vaccines; 2009 Jul; 8(7):851-61. PubMed ID: 19538112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
    Maiden MC; Ibarz-Pavón AB; Urwin R; Gray SJ; Andrews NJ; Clarke SC; Walker AM; Evans MR; Kroll JS; Neal KR; Ala'aldeen DA; Crook DW; Cann K; Harrison S; Cunningham R; Baxter D; Kaczmarski E; Maclennan J; Cameron JC; Stuart JM
    J Infect Dis; 2008 Mar; 197(5):737-43. PubMed ID: 18271745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.
    Campbell H; Andrews N; Borrow R; Trotter C; Miller E
    Clin Vaccine Immunol; 2010 May; 17(5):840-7. PubMed ID: 20219881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.
    MacLennan JM; Rodrigues CMC; Bratcher HB; Lekshmi A; Finn A; Oliver J; Wootton M; Ray S; Cameron C; Smith A; Heath PT; Bartolf A; Nolan T; Hughes S; Varghese A; Snape MD; Sewell R; Cunningham R; Stolton A; Kay C; Palmer K; Baxter D; Suggitt D; Zipitis CS; Pemberton N; Jolley KA; Bray JE; Harrison OB; Ladhani SN; Pollard AJ; Borrow R; Gray SJ; Trotter C; Maiden MCJ
    Lancet Infect Dis; 2021 May; 21(5):677-687. PubMed ID: 33482143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.
    Trotter CL; Edmunds WJ; Ramsay ME; Miller E
    Hum Vaccin; 2006; 2(2):68-73. PubMed ID: 17012888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
    Bröker M
    Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL; Gay NJ; Edmunds WJ
    Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of vaccination on meningococcal epidemiology.
    Stefanelli P; Rezza G
    Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys.
    Mbaeyi S; Sampo E; Dinanibè K; Yaméogo I; Congo-Ouédraogo M; Tamboura M; Sawadogo G; Ouattara K; Sanou M; Kiemtoré T; Dioma G; Sanon B; Somlaré H; Kyetega A; Ba AK; Aké F; Tarbangdo F; Aboua FA; Donnou Y; Kamaté I; Patel JC; Schmink S; Spiller MW; Topaz N; Novak R; Wang X; Bicaba B; Sangaré L; Ouédraogo-Traoré R; Kristiansen PA
    Lancet Infect Dis; 2020 Dec; 20(12):1418-1425. PubMed ID: 32653071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4CMenB vaccine and its role in preventing transmission and inducing herd immunity.
    McMillan M; Marshall HS; Richmond P
    Expert Rev Vaccines; 2022 Jan; 21(1):103-114. PubMed ID: 34747302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of meningococcal C conjugate vaccine in the UK.
    Balmer P; Borrow R; Miller E
    J Med Microbiol; 2002 Sep; 51(9):717-722. PubMed ID: 12358061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.